Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Interventional × Neurofibromatosis 2 × Clear all

Phase

Phase 2 16 Phase NA 7 Phase EARLY_PHASE1 2 Phase 1/2 2 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 97 Neoplasms 91 Carcinoma, Non-Small-Cell Lung 67 Colorectal Neoplasms 64 Prostatic Neoplasms 63 Carcinoma, Hepatocellular 58 Leukemia, Myeloid, Acute 52 Stomach Neoplasms 46 Neoplasm Metastasis 46 Precursor Cell Lymphoblastic Leukemia-Lymphoma 40 Lung Neoplasms 39 Pancreatic Neoplasms 35 Recurrence 31 Rectal Neoplasms 27 Multiple Myeloma 27 Colonic Neoplasms 25 Leukemia 24 Head and Neck Neoplasms 23 Ovarian Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 21 Lymphoma 21 Hematologic Neoplasms 20 Myelodysplastic Syndromes 18 Esophageal Neoplasms 18 Urinary Bladder Neoplasms 17 Polycystic Ovary Syndrome 17 Lymphoma, Large B-Cell, Diffuse 16 Melanoma 15 Liver Neoplasms 15 Glioblastoma 15

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡